NCT06590961

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 94 (estimated)
• Sponsor: Ubix Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.

Conditions

• Relapsed/Refractory B-cell Malignancies

Interventions

Type	Name	Description
DRUG	UBX-303061	UBX-303061 oral dosage

Timeline

• Start date: 2025-02-20
• Primary completion: 2027-08-01
• Completion: 2027-08-01
• First posted: 2024-09-19
• Last updated: 2025-11-19

Locations

11 sites across 3 countries: United States, Poland, South Korea

Regulatory

• FDA-regulated drug study